Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | Director · Chief Executive Officer | July 30, 2026 | August 03, 2026 |
| TerrAscend Corp.TSNDF · Entity 6184 | Director | June 24, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HERON THERAPEUTICS, INC. /DE/
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 856,492 |
Ending reported balance
After 2026-07-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-30 · Exercise / conversion · Acquired 50,021 · Balance 821,703 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2026-07-31 · Exercise / conversion · Acquired 34,789 · Balance 856,492 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 700,295 |
Reported balance
After 2026-07-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-30 · Exercise / conversion · Disposed 50,021 · Balance 700,295 F2: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 347,886 |
Reported balance
After 2026-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-31 · Exercise / conversion · Disposed 34,789 · Balance 347,886 F3: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein.
F3: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).
TerrAscend Corp.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.44 · Expires 2029-04-24 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Disposition to issuer · Disposed 150,000 · Balance 0 F1: See remarks. |
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2029-04-24 | Direct | 150,000 |
Reported balance
After 2026-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-24 · Grant · Acquired 150,000 · Balance 150,000 F1: See remarks. |
Filing footnotes · ownership attribution and instrument terms
F1: See remarks.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OPIANT PHARMACEUTICALS, INC.
Report date March 02, 2023 · Filed March 03, 2023
Section 16 reporting ended · disclosed 2023-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-02 · Disposition to issuer · Disposed 53,822 · Balance 2,000 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Row 2 · 2023-03-02 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.61 · Expires 2028-10-29 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-02 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.79 · Expires 2030-06-15 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2029-06-11 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2031-06-14 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
F3: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
Sierra Oncology, Inc.
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 1
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 13,500 · Balance 0 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2030-05-28 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1: The option fully vested on May 28, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.11 · Expires 2031-06-08 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-01 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F3: The option fully vested on June 8, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option fully vested on May 28, 2021.
F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
F3: The option fully vested on June 8, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 3, 2026 13:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 34,789 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-329694 · ownership.xml · derivative · entry 4 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,886 Underlying: Common Stock · 34,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 13:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 34,789 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-329694 · ownership.xml · nonDerivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 856,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 13:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 50,021 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-329694 · ownership.xml · derivative · entry 3 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,295 Underlying: Common Stock · 50,021 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein. F2 · derivative.expiration_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 13:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 50,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-329694 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 821,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| July 19, 2026 Filed Jul 20, 2026 20:22 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 13,797 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-308958 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,781 Underlying: Common Stock · 13,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| July 19, 2026 Filed Jul 20, 2026 20:22 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 13,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-308958 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 771,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 23:09 UTC | TerrAscend Corp. TSNDF · Entity 6184 | GrantEmployee Share Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $0.26 | Not disclosed |
DisclosureSEC source: 0002064832-26-000248 · form4.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2029-04-24 F1 · price: See remarks. F1 · derivative.exercise_date: See remarks. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 23:09 UTC | TerrAscend Corp. TSNDF · Entity 6184 | Disposition to issuerEmployee Share Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $6.44 | Not disclosed |
DisclosureSEC source: 0002064832-26-000248 · form4.xml · derivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 150,000 shares Expires 2029-04-24 F1 · price: See remarks. F1 · derivative.exercise_date: See remarks. Read SEC document |
| April 30, 2026 Filed May 4, 2026 15:30 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 50,021 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-203196 · ownership.xml · derivative · entry 4 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,316 Underlying: Common Stock · 50,021 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. F4 · derivative.expiration_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. Read SEC document |
| April 30, 2026 Filed May 4, 2026 15:30 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 34,789 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-203196 · ownership.xml · derivative · entry 3 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,675 Underlying: Common Stock · 34,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| April 30, 2026 Filed May 4, 2026 15:30 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 50,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-203196 · ownership.xml · nonDerivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 757,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · balance_after: Includes 11,023 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2026. Read SEC document |
| April 30, 2026 Filed May 4, 2026 15:30 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 34,789 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-203196 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 696,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 19, 2026 Filed Apr 21, 2026 13:41 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 13,797 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-165365 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,758 Underlying: Common Stock · 13,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| April 19, 2026 Filed Apr 21, 2026 13:41 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 13,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-165365 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 03, 2026 Filed Apr 6, 2026 23:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 62,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-144196 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| April 03, 2026 Filed Apr 6, 2026 23:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 62,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-144196 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 648,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · balance_after: Includes 14,045 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 13:30 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 34,789 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034490 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,464 Underlying: Common Stock · 34,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 13:30 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 34,789 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-034490 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 571,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 15:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantPerformance Stock Units · Derivative | 800,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034633 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,336 Underlying: Common Stock · 800,336 shares Expires not disclosed F3 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On January 30, 2026, the Reporting Person was granted 800,336 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein. F4 · derivative.expiration_date: On January 30, 2026, the Reporting Person was granted 800,336 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 15:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 800,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034633 · ownership.xml · derivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,337 Underlying: Common Stock · 800,337 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein. F2 · derivative.expiration_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein. Read SEC document |
| January 19, 2026 Filed Jan 20, 2026 19:39 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 13,797 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-016413 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,375 Underlying: Common Stock · 13,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| January 19, 2026 Filed Jan 20, 2026 19:39 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 13,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-016413 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 17:31 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 34,789 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-264032 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 452,253 Underlying: Common Stock · 34,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 17:31 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 34,789 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-264032 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| October 19, 2025 Filed Oct 21, 2025 15:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 13,797 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-244520 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,172 Underlying: Common Stock · 13,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| October 19, 2025 Filed Oct 21, 2025 15:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 13,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-244520 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 21:21 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 34,789 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-102150 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487,042 Underlying: Common Stock · 34,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 21:21 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 34,789 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-102150 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| July 19, 2025 Filed Jul 22, 2025 15:55 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 13,797 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-097488 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,969 Underlying: Common Stock · 13,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| July 19, 2025 Filed Jul 22, 2025 15:55 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 13,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-097488 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 439,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 20:57 UTC | TerrAscend Corp. TSNDF · Entity 6184 | GrantCommon Shares | 433,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-018197 · form4-06252025_080612.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,076,538 F1 · shares: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 34,789 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-063061 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 521,831 Underlying: Common Stock · 34,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 34,789 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-063061 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 19, 2025 Filed Apr 22, 2025 13:39 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 13,796 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-056488 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,766 Underlying: Common Stock · 13,796 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| April 19, 2025 Filed Apr 22, 2025 13:39 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 13,796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-056488 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 391,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 03, 2025 Filed Apr 3, 2025 21:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 62,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-050677 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 62,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| April 03, 2025 Filed Apr 3, 2025 21:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 62,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-050677 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| March 25, 2025 Filed Mar 26, 2025 21:06 UTC | TerrAscend Corp. TSNDF · Entity 6184 | Tax withholdingCommon Shares | 2,258 | $0.46 | $1,038.68 |
DisclosureSEC source: 0001415889-25-009042 · form4-03262025_090328.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 642,885 F1 · shares: Shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted share units pursuant to an equity plan administered by the Issuer. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 17:43 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 556,620 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013042 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 556,620 Underlying: Common Stock · 556,620 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 17:43 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,113,240 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000950170-25-013042 · ownership.xml · derivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,113,240 Underlying: Common Stock · 1,113,240 shares Expires 2035-01-31 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (January 31, 2025). Read SEC document |
| January 19, 2025 Filed Jan 22, 2025 14:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 13,797 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-007545 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,562 Underlying: Common Stock · 13,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| January 19, 2025 Filed Jan 22, 2025 14:06 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 13,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-007545 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · balance_after: Includes 10,683 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2024. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:05 UTC | TerrAscend Corp. TSNDF · Entity 6184 | Tax withholdingCommon Shares | 71,704 | $0.65 | $46,607.60 |
DisclosureSEC source: 0001415889-25-000386 · form4-01032025_090124.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645,143 F1 · shares: Shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted share units pursuant to an equity plan administered by the Issuer. Read SEC document |
| October 19, 2024 Filed Oct 21, 2024 19:49 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 13,797 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-115920 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,359 Underlying: Common Stock · 13,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| October 19, 2024 Filed Oct 21, 2024 19:49 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 13,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-115920 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 13:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 13,797 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-085096 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,156 Underlying: Common Stock · 13,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 13:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 13,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-085096 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:30 UTC | TerrAscend Corp. TSNDF · Entity 6184 | GrantShare Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $6.44 | $0.00 |
DisclosureSEC source: 0001415889-24-017691 · form4-06202024_050614.xml · derivative · entry 3 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2029-04-24 F2 · kind: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 24, 2019, and is fully vested. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 24, 2019, and is fully vested. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:30 UTC | TerrAscend Corp. TSNDF · Entity 6184 | Disposition to issuerShare Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $6.44 | $0.00 |
DisclosureSEC source: 0001415889-24-017691 · form4-06202024_050614.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 150,000 shares Expires 2024-04-24 F2 · kind: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 24, 2019, and is fully vested. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 24, 2019, and is fully vested. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:30 UTC | TerrAscend Corp. TSNDF · Entity 6184 | GrantCommon Shares | 163,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017691 · form4-06202024_050614.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 716,847 F1 · shares: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2024, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.